A Study of Dulaglutide in Healthy Participants

NCT03363906 · Completed

Last updated 2026-05-28

This clinical trial studied how the drug dulaglutide is absorbed and processed in the body of healthy participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 27 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2017-12 · est. completion 2018-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03363906 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe. This study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU).

Treatments tested

Dulaglutide (Reference) also known as LY2189265 Drug

Administered SC
Dulaglutide (Test) also known as LY2189265 Drug

Administered SC

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03363906 ↗